Kornimate/medical-research-clean huggingface dataset:
test-retest reliability of the german version of the headache disability questionnaire (hdq).

Conditions: Headache Disorders

Summary: a translated and cultural adapted version of the hdq will be tested on two occasions with headache patients who are currently in physiotherapeutic treatment due to their headache condition

the test-retest reliability of the german version of the hdq will be tested to assess the reproducibility of the test results with a stable condition of the participants over a short period of time. for this purpose, it is planned to administer the questionnaire twice in row at an interval of 48 - 72 hours to headache patients in outpatient physiotherapy. the chosen setting limits the sample to a common intervention measure (physiotherapy), so that primary and secondary headache types can be included and the requirements of the original study can be maintained. in the period between the two tests, subjects should not receive physiotherapy, because it can often have different effects on headache. this can lead to uneven changes in the sample and affect the variance of the test results. however, subjects are allowed to take their usual medications. to avoid recall bias, an online survey tool (redcap) to conduct the questionnaire will be used. it is designed so that, only one question appears per slide, no overview of responses is allowed and the questions are displayed in a different order at the second testing. the lower prevalence of headaches after the age of 65 years is taken into account in the inclusion criteria.

Eligibility criteria:
inclusion criteria: * within physiotherapeutic care due to headache for no longer than 3 months * headache conditions for at least one month and at least once /month * live in switzerland * give informed consent exclusion criteria: * not in physiotherapeutic care * in physiotherapeutic care due to other conditions not associated with headache * younger than 18 and older than 65 years
effects of respiratory muscle training in people who have had covid-19 disease

Conditions: Covid19; Respiratory Muscle Training; Respiratory Function Test; Quality of Life; Psychosocial Factor

Summary: the main objective of the present study is to observe the short-term effects of respiratory muscle training applied by telerehabilitation on quality of life and exercise tolerance in people who have had the covid-19 disease. as secondary objectives, the effects on respiratory muscles strength/tolerance, pulmonary function and psychological and cognitive factors.

it is a double-blind randomized clinical trial study. each participant will be randomly assigned to one of the following groups: 1) inspiratory muscle training, 2) placebo inspiratory muscle training, 3) inspiratory muscle training + expiratory muscle training, 4) placebo inspiratory muscle training + expiratory muscle training. each exercise training program will be applied twice per day 7 sessions per week during 8 weeks by a threshold device. the evening sessions will be supervised by a physiotherapist through a virtual platform. participants received baseline assessments at the beginning of the intervention, at the end of the 4th week, and post-intervention assessments at the end of the 8th week.

Eligibility criteria:
inclusion criteria: * positive diagnosis of covid-19 (sars-cov2) * hospital admission for covid-19 in the last 3 months * stable phase and home discharge; exclusion criteria: * severe cognitive impairment * any type of musculoskeletal, neurological, cardiac or respiratory disease where training is contraindicated * inability to carry out the training program through telematic supervision.

Keywords: covid-19 respiratory muscle training respiratory function test quality of life psychosocial factor
micro-electrodes implanted in a human nerve

Conditions: Amputations; Peripheral Nerve Injury; Spinal Cord Injury

Summary: the main objective of the intervention in the study is devise feasibility using high-count microelectrode arrays implanted into peripheral nerves of patients with limb amputations or peripheral nerve injury. these microelectrodes will be custom-made and are not available for commercial distribution. the investigators hypothesize that recording neural signals from a large number of microelectrodes will provide selective motor information in high enough numbers to allow control over future artificial devices with many moving parts, i.e. artificial limbs with shoulder, elbow, wrist, and/or individual fingers that move. these studies will also investigate to what extent microstimulation of nerve fibers can provide sensory feedback from a prosthetic limb. the investigators will also conduct up to three acute surgeries where a utah slanted electrode array (usea) will be implanted in volunteers who are about to undergo limb amputations. these acute implantations will provide dr. hutchinson with human surgical experience in implanting useas and evaluating the containment system we will be using to immobilize the implanted usea in the nerve.


Eligibility criteria:
inclusion criteria: * at least 18 years of age and less than 65 years of age * amputations * peripheral nerve injury * twelve participants for the 30 day implantation/physiological experimentation study * three participants for the acute surgical implantation part of the study exclusion criteria: * incarceration * pregnancy * inability to consent * psychiatric comorbidity * increase the risk of adverse effects of general anesthesia

Keywords: micro-electrodes peripheral nerve injury amputation spinal cord injury
perioperative chemotherapy combined with hipec for high-risk advanced gastric cancer

Conditions: Survival

Summary: the investigators intend to conduct a randomized controlled study to find if combining hipec (hyperthermic intraperitoneal perfusion chemotherapy) with post-neoadjuvant chemotherapy d2 resection could improve survival for patients with advanced gastric cancer, while comparing with the traditional approach of d2 resection after neoadjuvant chemotherapy.

gastric cancer, as the second common malignant tumors in china, is marked by its poor prognosis and high recurrent rate. although r0 resection could be achieved in most advanced gastric cancer(agc) patients without metastasis, age-standardized 5-years survival rate was no more than 27.4%. peritoneal metastasis accounts for 50% of the recurrent case and remain to be the most fatal recurrence pattern. hyperthermic intraperitoneal perfusion chemotherapy ( hipec ), has been proved as one of the most efficient approach against peritoneal carcinomatosis from gastric cancer and recommended in the guideline for gastric cancer published by the health committee of china. however, its role as prophylactic treatment after curative has never been determined. hipec works by delivering heat and cytotoxic drug to the cancer cell and is more effective on the tumor with small size. as present study suggest that peritoneal metastasis is related to lymph node dissection during surgery while opening lymphatic channels and spreading viable cancer cells into the peritoneal cavity, hipec might be a reasonable approach to destroy the remaining cancer cells after curative surgery. thus this research aim to explore the efficacy and safety of combining hipec (hyperthermic intraperitoneal perfusion chemotherapy) with post-neoadjuvant chemotherapy d2 resection.

Eligibility criteria:
inclusion criteria: 1. first diagnosed as gastric cancer by pathological examination; 2. no previous chemotherapy or radiotherapy; 3. t stage:3-4, n stage: 1-3, m stage: 0, assessed by ct or ultrasound endoscope; 4. eastern cooperative oncology group performance status (ecog ps): 0-1; 5. informed consent signed; exclusion criteria: 1. other malignancy within 5 years. 2. peritoneal metastasis detected during surgery. 3. pregnant or lactating women; 4. patients with conditions requiring emergency surgery; 5. tumor progress during neo-adjuvant chemotherapy 6. severe, uncontrolled physical or metal disease. 7. poor compliance. 8. uncontrolled infection

Keywords: intraperitoneal chemotherapy gastric cancer neo-adjuvant chemotherapy
providing patient information and ct examination results

Conditions: Chest Pain; Nonmalignant Condition

Summary: chest pain is a common cause of visits in the emergency room and general practice, and is most commonly connected as a symptom of coronary disease, as for instance angina pectoris and acute myocardial infarct. approximately 75-80% of these patients are not diagnosed with coronary disease or other cardiac findings. however, many of these patients still report chest pain and worries about cardiac disease. this study is based on patients that are referred to a ct-examination of the coronary arteries on the background of chest pain, where the ct-examination shows normal coronary arteries. the study aims to evaluate whether providing an intervention to this group of patients has an effect on patient satisfaction, patient's worry of cardiac disease and incidence of chest pain. the intervention group will be compared with a similar group going through the same ct-examination, but is receiving the examination result from their regular general practitioner (rgp), which is considered standard care. the hypothesis is that patients with chest pain with no coronary findings receiving extended information before getting the normal examination results experience a better patient satisfaction than those receiving the examination result from their rgp.

this study is a randomized controlled study. eligible patients going through a ct-examination of the heart's coronary arteries, coronary ct angiogram (ccta) will after an informed consent be randomized into two groups, either the intervention group or standard care. the intervention consists of extended information regarding the benefits of doing a ccta, thereby emphasising the specificity and accuracy of the ccta's ability to exclude coronary disease. after this, there will be given an opportunity of a visual go-through and explanation of ct-images. then they will be informed of the examination result that shows normal coronary arteries. follow up is planned after one month, six months and twelve months, where the participants receive the same questionnaire as at baseline to fill out and return. the questionnaire consists of seattle angina questionnaire and rand-12, in addition to social demographic and clinical data, such as sex, height, weight and current medication.

Eligibility criteria:
inclusion criteria: * ability to speak and read norwegian fluently * competent to give informed consent * referred from cardiologist * experienced chest pain * calcium score = 0 and ccta must show normal coronary arteries * received information letter on ongoing research in the heart department of haukeland university hospital exclusion criteria: * admitted patients * heart disease or coronary anomalies shown on the ccta

Keywords: non coronary chest pain extended information normal examination result coronar computed tomography angiography ccta calcium score diagnostic examination patient satisfaction normal coronary arteries
optimal cardiac resynchronization therapy pacing rate

Conditions: Cardiac Resynchronization Therapy; Heart Failure; Bi-ventricular Pacing; Sympathetic Activity; Quality of Life

Summary: the optimal pacing rate during cardiac resynchronization therapy (crt) is not known. investigators investigate the impact of changing basal pacing frequencies on autonomic nerve function, cardiopulmonary exercise capacity and self-perceived quality of life (qol).

this is a double-blinded randomized crossover pilot study testing two basal pacing rates: ddd-60 versus ddd-80. each patient is paced for 2 periods of 90 days with ddd-60 and ddd-80 in a randomly sequence. blood samples nt-probnp plasma levels are analysed at baseline and at the end of each phase using electrochemiluminescence-immunoassay. patients rest for 15 minutes before the samples are taken. these result are monitored by supervisory group to ensure that increase of more than 15% than baseline values result in termination of study. investigators conduct two distinct questionnaires (minnesota living with heart failure (lifhe) questionnaire and medical outcome survey short form (sf-36)) a symptom limiting bicycle (ergoline, baden-württemberg, germany) exercise test is performed to measure maximum work capacity and oxygen consumption at each phase. recordings of resting muscle sympathetic nerve activity (msna) are sought in all patients at both rates of pacing. all patients are studied on the same set-up in the semi-recumbent position after 30 minutes of rest. tungsten microelectrodes (iowa bioengineering) are inserted into the common peroneal nerve just below the knee.

Eligibility criteria:
inclusion criteria: * diagnosis with idiopathic dilated cardiomyopathy * crt device implanted (with initial indication in accordance with european guidelines) at least 6 months prior to inclusion. * new york heart association functional (nyha) class ii-iv * sinus rhythm, * hemodynamically stable * biventricular pacing \> 90% of the time * on optimal medical treatment for heart failure with no changes in medications during the past 3 months. exclusion criteria: * nyha i * unable to perform exercise test (e.g. chronic obstructive pulmonary disease, severe arthritis) * cancer * plasma creatinine \> 200 micromole per litre * an admission for decompensated hf or acute coronary syndrome in the preceding 3 months.
the effects of airtrapping on sleep and breathing in non invasive ventilation (niv) in copd

Conditions: COPD; Hypercapnic Respiratory Failure

Summary: 15 copd patients will be surveyed in this prospective randomized crossover pilot study concerning non invasive ventilation. patients will be treated over 2 nights in randomized order with ventimotion2 (weinmann) with and without airtrap control under polysomnography (psg) surveillance including transcutaneous pco2 measurement. the sleep quality is judged by evaluating the psg and pco2 values over night. target parameters are respiratory rate, sleep quality and influence of airtrap control on pco2 values over night.


Eligibility criteria:
inclusion criteria: * stable respiratory situation * clinically required niv * capable of giving consent exclusion criteria: * invasive ventilation * any other severe physical disease that requires immediate medical assistance * acute hypercapnic decompensation with ph \<7.30 in routine bga * circumstances that doesn't allow mask ventilation (e.g. facial deformation) * participation in a clinical trial within the last 4 weeks * pregnancy or nursing period * drug addiction

Keywords: copd niv airtrapping ventimotion2
shortening duration of antiarrhythmic medication for svt in infants

Conditions: Supraventricular Tachycardia

Summary: the infants diagnosed with svt are treated with antiarrhythmic medication to prevent the recurrence of svt. this prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with svt. primary outcome is incidence of recurrent svt in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.


Eligibility criteria:
inclusion criteria: * age 6 months or less * documented svt due to avrt or avnrt exclusion criteria: * age \> 6 months * ectopic atrial tachycardia * atrial flutter * atrial fibrillation * permanent junctional reciprocating tachycardia

Keywords: tachycardia, supraventricular anti-arrhythmia agents arrhythmias, cardiac
resident surveillance of pediatric patient developmental status at the two month preventive care visit

Conditions: Growth & Development; Child Development; Internship and Residency; Education, Medical; Developmental Disabilities

Summary: the purpose of this study is to evaluate the efficacy of individualized performance feedback coupled with an educational module in improving resident performance of the physical and developmental examination component of developmental surveillance of infants at the two month preventive care visit.

many children in the united states have developmental or behavioral disabilities. the american academy of pediatrics recently published a policy statement outlining recommendations for developmental surveillance and screening of infants and young children. one of the academy's recommendations was for inclusion of developmental surveillance during all preventive care visits. the five components of developmental surveillance include elicitation and attendance to parental concerns, maintenance of the developmental history, observation of the child through physical and developmental examinations, identification of risk and protective factors, and documentation of surveillance findings and process (referral, follow-up, etc.). as a result of concerns expressed by the public regarding accountability in medical education and health care, the accreditation council for graduate medical education and the american board of medical specialties mandated that training programs shift to a competency based assessment system. the focus of this study will be to assess the impact of performance feedback (based upon video recorded observation) coupled with an educational module on resident demonstration of competency in regard to the physical and developmental examinations component of developmental surveillance of infants at the two month preventive care visit.

Eligibility criteria:
inclusion criteria: * categorical pediatric residents in their second year of training at children's mercy hospitals and clinics who are scheduled to see infants for a two month preventive care visit. exclusion criteria: * preventive care visits for infants who have parents/guardians who do not speak english fluently * preventive care visits for infants who have a previously identified genetic or other medical syndrome or developmental delay

Keywords: growth and development child development developmental surveillance medical education internship and residency
acei arb withdrawal in ckd patients

Conditions: Chronic Kidney Disease; Blood Pressure; Angiotensin-converting Enzyme Inhibitor; Angiotensin Receptor Blockers

Summary: the american heart association guidelines for high blood pressure (bp) currently recommend using angiotensin-converting enzyme inhibitors (acei) or angiotensin receptor blockers (arbs) as first-line therapy for patients with chronic kidney disease (ckd) stage 3 or above. however, the prevalence of acei and arb use in patients with ckd stage 4 or 5 is low, and current bp guidelines acknowledge the lack of solid evidence to support the benefit of using these agents in advanced ckd.this study seeks to conduct a pilot trial to determine the safety and feasibility of acei and/or arb continuation (intervention) versus withdrawal (control) in patients with advanced ckd.


Eligibility criteria:
inclusion criteria: * adults ≥18 years of age who meet the egfr eligibility criteria, which will be determined based on whether participants have at least two egfr in the last three months that are \< 25 ml/min/1.73m2 or prior diagnosis of ckd (per electronic chart review) and at least one egfr \< 25 ml/min/1.73m2 in the past six months * receiving at least one antihypertensive medication at the time of the screening visit. exclusion criteria: the investigators will exclude those who: * are or are planning to become pregnant, due to inability to take multiple classes of anti-hypertensive agents * are marginally housed, due to concerns regarding routine follow-up * are actively participating in a different interventional trial that may affect blood pressure * are unwilling to consent to participate * institutionalized individuals or prisoners * are actively abusing illicit drugs or alcohol * have a history of poor or doubtful compliance (e.g., frequently missed appointments) * have cognitive impairment prohibiting participation in the study * on dialysis at time of recruitment
study to evaluate cognitive functioning in remitted depression during treatment with fluvoxamine

Conditions: Recurrent Depressive Disorder

Summary: open label, non-comparative, prospective study to evaluate cognitive functioning in remitted depression outpatients during long-term preventive treatment with fluvoxamine (fevarin®)


Eligibility criteria:
inclusion criteria: 1. diagnosis of recurrent depressive disorder at least two years prior to enrollment into the study. 2. at least two severe depressive episodes with or without psychotic symptoms in the past medical history. 3. stable patient in remission since at least 4 weeks after depressive episode and not more than 6 months after depressive episode. 4. planned prescription of fluvoxamine for preventive therapy in recurrent depressive disorder. 5. the subject is fluent in russian language. 6. according to stroop test one of following points has to be met - increase of the words reading time on 10% and more or three and more mistakes done. 7. sum of addenbrooke's cognitive examination total scores must be 93 or less. 8. male or female, between the ages of 18 and 65 years. 9. if female, postmenopausal or birth control. exclusion criteria: 1. diagnosis of the following concomitant psychiatric disorders: current depressive or maniac episode, bipolar affective disorder, persistent mood affective disorder (cyclothymia, dysthymia, other or unspecified persistent mood disorder), other or unspecified mood affective disorder, substance-related disorders, schizophrenia, or other psychotic disorders. 2. history of a drug or alcohol disorder. 3. current treatment with fluvoxamine. 4. history of depressive disorder associated with endocrine disorders. 5. pregnancy, breast-feeding female patients. 6. history of any significant neurologic disease. 7. treatment with electroconvulsive therapy in the 6 months preceding the study. 8. major risk of suicide. 9. hypersensitivity to fluvoxamine. 10. use of the medications, which are known to interact with fluvoxamine. 11. have initiated psychotherapy or other therapies (such as acupuncture or hypnosis). 12. have initiated cognitive remediation therapy within 12 weeks prior enrollment or at any time during the study.

Keywords: cognitive function